https://doi.org/10.4081/monaldi.2021.1759
Association of cycle threshold values of CBNAAT with severity and outcome in COVID-19
Accepted: June 8, 2021
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Determination of viral load through cycle threshold (Ct) values may act as a predictor of severity and outcomes in patients with corona virus disease 2019 (COVID-19). However, variable literature is available regarding this relationship. Our study attempted to explore this association and the effect of various socio-demographic and clinical parameters on severity and outcome of COVID-19. Retrospective analysis of records of 731 patients whose nasopharyngeal/oropharyngeal swabs were subjected to cartridge based nucleic acid amplification (CBNAAT) on Cepheid Xpert Xpress SARS-CoV-2 was done. Ct values of N2 and E genes were studied in relation to severity and outcome of COVID-19. The viral load as determined by Ct values was classified as high (<25), medium (25.1-32) and low (>32). Association of socio-demographic and clinical parameters with respect to severity and outcome was also studied. Severity and mortality were significantly more in elder individuals, those belonging to the rural background, those with symptoms >7 days in duration before presentation and those with increasing number of co-morbidities (severity: p<0.001; mortality: p<0.001, 0.005, 0.006 and <0.001, respectively). The Ct values of gene N2 and E inversely correlated with severity and mortality from the disease (N2 gene: p=0.001 for both severity and mortality, E gene: severity: p<0.001, mortality: p=0.016, respectively). The severity of the illness and chances of mortality were significantly lesser when the CT value of N2 gene was >32, in comparison when it was upto 25, and when between 25.1 and 32 (severity: p=0.032 and 0.003, respectively; mortality: p=0.018 and <0.001, respectively). Almost similar trends were seen with respect to E gene (severity: p<0.001 and 0.067, respectively; mortality p=0.175 and 0.005, respectively). Viral load as determined by Ct values of N2 and E genes can act as surrogate markers for prediction of severity and disease outcomes in COVID-19.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Neeta Singla, Amitesh Gupta, U.K. Khalid, Ravindra Kumar Dewan, Rupak Singla, Clinical profile, risk factors, disease severity, and outcome for COVID-19 disease in patients with tuberculosis on treatment under the National Tuberculosis Elimination Program: a cohort of 1400 patients , Monaldi Archives for Chest Disease: Early Access
- Amrutha S, Komaldeep Kaur, Deepak Aggarwal, Mandeep Kaur Sodhi, Shivani Jaswal, Varinder Saini, Serial evaluation of antibody titres in patients recovered from COVID-19 and their correlation with disease severity , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Frederico Ribeiro Neto, Juliane Machado Marques, Matheus Brasiliano da Paz, Eduardo Boiteux Uchôa Cavalcanti, Rodrigo Rodrigues Gomes Costa, Sit-to-stand test and handgrip strength in men and women with post-COVID-19 syndrome without invasive ventilator support: insights from a Brazilian observational study , Monaldi Archives for Chest Disease: Vol. 94 No. 3 (2024)
- Gaukhar Kurmanova, Almas Zhanaev, Akzharkyn Kaldybek, Balkiya Abdrakhmanova, Almira Akparova, Impact of the COVID-19 pandemic on the clinical features of patients with chronic obstructive pulmonary disease: an observational cross-sectional study , Monaldi Archives for Chest Disease: Early Access
- Angelica Cersosimo, Mattia Di Pasquale, Gianmarco Arabia, Marco Metra, Enrico Vizzardi, COVID myocarditis: a review of the literature , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Sunny Kumar, Saurabh Mehra, Mrinal Sircar, Onkar Jha, Rajesh Gupta, Seema Sinha, Ravneet Kaur, Evaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study , Monaldi Archives for Chest Disease: Early Access
- Megha Hegde, Saurav Raj, Dhananjay Tikadar, Sanatkumar B Nyamagoud, Unveiling vaccine safety: a narrative review of pharmacovigilance in India’s COVID-19 vaccination , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Matteo Vigna, Piero Ceriana, Mara Santomassimo, Michele Vitacca, Mauro Maniscalco, Nicolino Ambrosino, Effects of pulmonary rehabilitation in survivors of severe acute respiratory syndrome coronavirus 2. Role of vaccination , Monaldi Archives for Chest Disease: Vol. 94 No. 3 (2024)
- Federico Raimondi, Stefano Centanni, Fabrizio Luppi, Stefano Aliberti, Francesco Blasi, Paola Rogliani, Claudio Micheletto, Marco Contoli, Alessandro Sanduzzi Zamparelli, Marialuisa Bocchino, Paolo Busatto, Luca Novelli, Simone Pappacena, Luca Malandrino, Giorgio Lorini, Greta Carioli, Fabiano Di Marco, Respiratory rate-oxygenation index on the 3rd day is the best predictor of treatment failure in COVID-19 patients , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Andrea Segreti, Francesco Piccirillo, Simone Pasquale Crispino, Francesca Cocchia, Arianna Martucciello, Vito Calabrese, Fiorella Gurrieri, Francesco Grigioni, Simultaneous presence of Brugada and overgrowth syndromes , Monaldi Archives for Chest Disease: Vol. 94 No. 1 (2024)
You may also start an advanced similarity search for this article.
